Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction
This study evaluated the effects of dulaglutide vs placebo on liver and glycaemic/metabolic measurements in a population with Type 2 diabetes and in a subgroup with non-alcoholic fatty liver/non-alcoholic steatohepatitis.Once-weekly dulaglutide improved alanine aminotransferase, aspartate transaminase and gamma-glutamyl transpeptidase levels compared with placebo in a pattern consistent with liver fat reductions. Our results add further weight to the notion that glucagon-like peptide-1 receptor agonists may provide benefit in lowering liver fat in addition to their other metabolic actions.
Read more: https://www.ncbi.nlm.nih.gov/pubmed/29869810
Cusi, K. , Sattar, N. , García‐Pérez, L. , Pavo, I. , Yu, M. , Robertson, K. E., Karanikas, C. A. and Haupt, A. (2018), Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. Diabet. Med.. Accepted Author Manuscript. . doi:10.1111/dme.13697